[Association of systemic lupus erythematosis and myasthenia gravis. A new case report].
The association of myasthenia gravis (MG) and systemic lupus erythematosus (SLE) is a quite rare one. We report here one case and try to discuss the physiopathologic mechanisms and also the clinical, evolutive and therapeutic features of this morbid association. It's the case of a woman of 43 years old followed in our department since 1999. The patient has been treated by corticosteroids (prednisone) with monthly administered cyclophospamide pulses. Nine months lately, she develops a diplopia with a ptosis, a dysphagia and a muscular weakness. The treatment was mainly based on intravenous immunoglobulins. The later evolution was favourable. The coexistence of SLE and MG is not casual. It must be considered in every lupic patient developing neuromuscular troubles.
Louzir
Bassem
B
Service de Médecine Interne, Hôpital Militaire Principal d'Instruction de Tunis, Montfleury, Tunis.
Ben Abdelhafidh
Nadia
N
Bahri
Meriem
M
M'Sadek
Fehmi
F
Ksontini
Imen
I
Boussema
Ezzeddine
E
Othmani
Salah
S
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology
D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide